Literature DB >> 28625830

Bioengineering strategies for inducing tolerance in autoimmune diabetes.

Steinunn Baekkeskov1, Jeffrey A Hubbell2, Edward A Phelps3.   

Abstract

Type 1 diabetes is an autoimmune disease marked by the destruction of insulin-producing beta cells in the pancreatic islets. Strategies to delay onset or prevent the autoimmune recognition of beta cell antigens or T cell-mediated killing of beta cells have mainly focused on systemic immunomodulation and antigen-specific immunotherapy. To bridge the fields of type 1 diabetes immunology and biomaterials engineering, this article will review recent trends in the etiology of type 1 diabetes immunopathology and will focus on the contributions of emerging bioengineered strategies in the fight against beta cell autoimmunity in type 1 diabetes.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmunity; Biomaterials; Tolerance; Type 1 diabetes

Mesh：

Year:  2017        PMID： 28625830     DOI： 10.1016/j.addr.2017.06.007

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN： 0169-409X            Impact factor:   15.470


  9 in total

Review 1.  Active targeted delivery of immune therapeutics to lymph nodes.

Authors:  Baharak Bahmani; Ishaan Vohra; Nazila Kamaly; Reza Abdi
Journal:  Curr Opin Organ Transplant       Date:  2018-02       Impact factor: 2.640

Review 2.  Bioconjugate Strategies for the Induction of Antigen-Specific Tolerance in Autoimmune Diseases.

Authors:  Chunsong Yu; Jingchao Xi; Meng Li; Myunggi An; Haipeng Liu
Journal:  Bioconjug Chem       Date:  2017-12-06       Impact factor: 4.774

Review 3.  Controlling timing and location in vaccines.

Authors:  Darrell J Irvine; Aereas Aung; Murillo Silva
Journal:  Adv Drug Deliv Rev       Date:  2020-06-26       Impact factor: 15.470

Review 4.  Red Blood Cell Membrane Processing for Biomedical Applications.

Authors:  Luigia Rossi; Alessandra Fraternale; Marzia Bianchi; Mauro Magnani
Journal:  Front Physiol       Date:  2019-08-20       Impact factor: 4.566

5.  Nanoparticles versus Dendritic Cells as Vehicles to Deliver mRNA Encoding Multiple Epitopes for Immunotherapy.

Authors:  Rebuma Firdessa-Fite; Rémi J Creusot
Journal:  Mol Ther Methods Clin Dev       Date:  2019-11-11       Impact factor: 5.849

Review 6.  Extracellular Vesicle Therapy for Type 1 Diabetes.

Authors:  Setareh Soltani; Kamran Mansouri; Mohammad Sajad Emami Aleagha; Narges Moasefi; Niloofar Yavari; Seyed Kazem Shakouri; Sara Notararigo; Ali Shojaeian; Flemming Pociot; Reza Yarani
Journal:  Front Immunol       Date:  2022-04-08       Impact factor: 8.786

Review 7.  Altered Function of Antigen-Presenting Cells in Type 1 Diabetes: A Challenge for Antigen-Specific Immunotherapy?

Authors:  Rémi J Creusot; Jorge Postigo-Fernandez; Nato Teteloshvili
Journal:  Diabetes       Date:  2018-08       Impact factor: 9.461

Review 8.  Nanotechnology in Immunotherapy for Type 1 Diabetes: Promising Innovations and Future Advances.

Authors:  Saumya Nigam; Jack Owen Bishop; Hanaan Hayat; Tahnia Quadri; Hasaan Hayat; Ping Wang
Journal:  Pharmaceutics       Date:  2022-03-15       Impact factor: 6.321

Review 9.  Local Immunomodulatory Strategies to Prevent Allo-Rejection in Transplantation of Insulin-Producing Cells.

Authors:  Xi Wang; Natalie K Brown; Bo Wang; Kaavian Shariati; Kai Wang; Stephanie Fuchs; Juan M Melero-Martin; Minglin Ma
Journal:  Adv Sci (Weinh)       Date:  2021-07-14       Impact factor: 16.806
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.